Toll‐Like Receptor 8 is a Therapeutic Target in Rheumatoid Arthritis
Arthritis & Rheumatology · 10.05.2026
DOI: 10.1002/art.70175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 10.05.2026. Verfasst von Yilan Guo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Toll Biotech Co., Ltd., Beijing, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Outstanding Young Scientist Program, National high level hospital clinical research funding.
Abstract (Originalsprache)
Objective
This study aimed to explore the pathogenic role of Toll‐like receptor 8 (TLR8) in rheumatoid arthritis (RA) and evaluate its potential as a therapeutic target. Using a combination of in vitro and in vivo models, we explored the functional involvement of TLR8 in RA pathogenesis and assessed the efficacy of TLR8 inhibition.
Methods
Gene expression profiles of patients with RA and healthy controls were analyzed to identify up‐regulated genes and pathways. In vitro RA models were established using fibroblast‐like synoviocytes (FLSs) from patients with RA, human umbilical vein endothelial cells, and peripheral blood mononuclear cells from patients with RA and RA monkeys and to examine TLR8's role in synoviocyte proliferation, angiogenesis, and inflammation. Additionally, the therapeutic efficacy of a TLR8 inhibitor was evaluated in collagen‐induced arthritis (CIA) mouse and RA rabbit models.
Results
TLR8 is aberrantly overexpressed in patients with RA and shows strong positive correlations with disease activity. Mechanistically, the up‐regulation and activation of TLR8 drives RA progression by promoting synovial hyperplasia, angiogenesis, and inflammation. Notably, TLR8 inhibition effectively alleviates these pathologic processes. In preclinical models, including a CIA mouse model and an RA rabbit model, TLR8 antagonists demonstrated significant therapeutic efficacy, reducing disease severity and ameliorating joint damage.
Conclusion
TLR8 promotes RA pathogenesis and could serve as a novel therapeutic target for RA. image
Autor:innen und Institutionen
- Toll Biotech Co., Ltd., Beijing, China.
- State Key Laboratory of Membrane Biology, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.
- Tsinghua-Peking Center for Life Sciences, Key Laboratory of Bioorganic Phosphorous Chemistry and Chemical Biology (Ministry of Education), Tsinghua University, Beijing, China.
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
- National Biomedical Imaging Center, Peking University, Beijing, China.
- Institute of Molecular Medicine, College of Future Technology, Peking University, Beijing, China.
Förderung
- National Natural Science Foundation of China
- Beijing Outstanding Young Scientist Program
- National high level hospital clinical research funding
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Natural Science Foundation of Beijing, China
- Chinese National Key Technology R&D Program
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Guo, Y., Zhu, T., Zhang, X., Gao, M., Su, C., Xiao, Y., Han, R., Xiang, X., Guo, S., Zheng, W., Lian, J., Wang, M., Zhang, X., Li, J., & Yin, H. (2026). Toll‐Like Receptor 8 is a Therapeutic Target in Rheumatoid Arthritis. Arthritis & Rheumatology. https://doi.org/10.1002/art.70175
Vancouver
Guo Y, Zhu T, Zhang X, Gao M, Su C, Xiao Y, et al. Toll‐Like Receptor 8 is a Therapeutic Target in Rheumatoid Arthritis. Arthritis & Rheumatology. 2026. doi:10.1002/art.70175
BibTeX
@article{Guo2026,
author = {Guo, Yilan and Zhu, Tong and Zhang, Xiaoqiao and Gao, Meng and Su, Chaofei and Xiao, Yu and Han, Ruiwen and Xiang, Xuwen and Guo, Shuning and Zheng, Wen and Lian, Jingjing and Wang, Meng and Zhang, Xiuqin and Li, Jing and Yin, Hang},
title = {Toll‐Like Receptor 8 is a Therapeutic Target in Rheumatoid Arthritis},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70175}
}
EUVIMED